Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
NCT ID: NCT04932291
Last Updated: 2023-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
210 participants
INTERVENTIONAL
2021-03-26
2023-11-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vafidemstat 1.2mg
Vafidemstat is administered as capsules.
vafidemstat
1.2mg capsule
placebo
Placebo is administered as capsules.
Placebo
placebo capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vafidemstat
1.2mg capsule
Placebo
placebo capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
4. Outpatient known to the site or investigator and has been treated by the site or investigator for at least the last 3 months prior to the Screening visit.
5. Stable living environment for \> 6 months before the Screening visit.
6. Body mass index (BMI) of at least 18.5 kg/m2, but no more than 35 kg/m2.
7. Willing and able to adhere to the prohibitions, restrictions and requirements specified in this protocol.
8. Otherwise, healthy, and medically stable based on medical history.
9. Clinical and neurological examinations and laboratory tests, as well as 12-lead ECG performed during screening that confirms subject is healthy and medically stable.
10. Able to read and write fluently and must have adequate hearing and visual acuity to complete the required testing outlined in this protocol.
11. Stable in their permitted regimen of background therapy as per drug labeling for concomitant medications at the Screening visit and they should maintain treatment throughout the study and not initiate any prohibited medications during the trial. Subjects should agree to inform their study physician of any medication changes throughout the trial.
12. Enrolled subjects will need to maintain their pre-screening psychotherapy schedule throughout the trial duration. That is, subjects receiving psychotherapy will need to have it started at least 3 months before the Screening visit and remain in psychotherapy throughout the trial. Subjects not receiving psychotherapy should not initiate psychotherapy during the trial.
13. Fertile male and female subjects must use highly efficient contraception, from the Screening visit until 30 days after last dose of the IMP, defined as:
A method with less than 1% failure rate (e.g., permanent sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner) OR The use of two methods of contraception (e.g., one barrier method \[condom, diaphragm or cervical/vault caps\] with spermicide and one hormonal contraceptive \[e.g., combined oral contraceptives, patch, vaginal ring, injectable and implants\])
14. Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline.
15. Signed informed consent by participant prior to the initiation of any study specific procedure.
1. DSM-5 diagnosis of intellectual disability, autism spectrum disorder, schizophrenia, schizoaffective disorder, bipolar disorder (or related disorders) or major depressive disorder (MDD) with psychosis.
2. Current DSM-5 diagnosis of conduct disorder, anorexia nervosa, bulimia nervosa, binge-eating disorder, oppositional defiant disorder, paranoid personality disorder or obsessive-compulsive disorder.
3. Current DSM-5 diagnosis of panic disorder or post-traumatic stress disorder (PTSD). However, subjects with PTSD, generalized anxiety disorder (GAD), social anxiety disorder (SAD), MDD without psychosis, attention deficit hyperactivity disorder (ADHD) are eligible if symptoms have been stable for at least 90 days prior to the Screening visit, these disorders are not the primary focus of treatment, changes in any treatment for these disorders would not likely be required for the duration of the study, and in the investigator´s opinion these disorders will not interfere with the assessment and/or accuracy of the study endpoints.
4. History of moderate or severe substance or alcohol use disorder according to DSM-5, with the exception of nicotine and caffeine, within 6-months before screening.
5. Use of illicit drugs for at least one week before Screening and subjects unwilling to abstain from use of these substances during the study.
6. Hospitalization or medication change for any reason, two months prior to the Screening visit or during the Screening period, that makes the subject medically or mentally unsuitable for trial participation.
7. Clinically significant, advanced or unstable disease that is likely to result in rapid deterioration of the subject's condition or affect their safety during the study.
8. Positive results for tuberculosis, Human Immunodeficiency Virus (HIV), Hepatitis C or Hepatitis B serology obtained at the Screening Visit.
9. Uncontrolled hypo- or hyperthyroidism at Screening Visit, based on laboratory parameters.
10. Clinically significant infection within the previous 30-days.
11. Chronic drug intake of specific forbidden medication
12. Esketamine in the past 90 days before the Screening visit.
13. Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in the past 90 days before the screening visit.
14. Any regular intake of medications acting directly on central nervous system that investigator considers relevant to the study.
15. Member or immediate family of the study personnel or subordinate to any of the study personnel.
16. Enrollment in another investigational study or intake of investigational drug within the previous 3 months.
17. Suicide attempt within the 6-month prior to the Screening visit or significant risk of suicide.
18. Any condition that in the opinion of the investigator makes the subject unsuitable for inclusion in the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oryzon Genomics S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Ropacki, MD
Role: STUDY_DIRECTOR
Oryzon Genomics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Excell Research Inc
Oceanside, California, United States
Excell Research, Inc.
Oceanside, California, United States
New Life Medical Research Center
Hialeah, Florida, United States
Phoenix Medical Research LLC
Miami, Florida, United States
University of Chicago Institutional Review Board
Chicago, Illinois, United States
Revive Research Institute
Elgin, Illinois, United States
Adams Clinical Trials, LLC
Watertown, Massachusetts, United States
Center for Emotioal Fitness
Cherry Hill, New Jersey, United States
Neurobehavioral Research Inc.
Cedarhurst, New York, United States
The Medical Research Network
New York, New York, United States
Core Clinical Research
Everett, Washington, United States
Medical Center Intermedika
Sofia, Sofia-Grad, Bulgaria
Medical Center Hera EOOD - Psychiatry Office
Sofia, Sofia-Grad, Bulgaria
DCC "Mladost-M" Ltd, Psychiatr
Varna, , Bulgaria
Klinik fur Psychiatrie und Psychotherapie, LMU
München, Bavaria, Germany
Emovis GmbH
Berlin, , Germany
Clinic for psychiatric disorders "Laza Lazarevic"
Belgrade, , Serbia
Clinical center of Serbia
Belgrade, , Serbia
Clinical center Kragujevac
Kragujevac, , Serbia
Hospital Vall d'Hebron
Barcelona, , Spain
Hospital Clínico San Carlos
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL07-ORY-2001
Identifier Type: -
Identifier Source: org_study_id